Literature DB >> 15831271

Screening tests for hepatocellular carcinoma.

Jorge A Marrero1.   

Abstract

The incidence of hepatocellular carcinoma (HCC) is rising throughout the world. HCC meets the criteria for which a disease benefits from screening or surveillance: it is an important health problem; those with cirrhosis are the targets for surveillance; there is acceptable treatment if diagnosed early; surveillance using alpha-fetoprotein and ultrasound has been shown to be cost effective; surveillance is widely implemented by health care professionals and accepted by patients; standardized recall procedures exists; and the screening tests must achieve an acceptable level of accuracy in the population undergoing screening. The latter point is the main limitation of surveillance for HCC. In this review we will discuss the currently available tests for the surveillance of HCC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15831271     DOI: 10.1016/j.cld.2004.12.006

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  28 in total

1.  Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas.

Authors:  Jian-Hua Luo; Baoguo Ren; Sergei Keryanov; George C Tseng; Uma N M Rao; Satdarshan P Monga; Steven Strom; Anthony J Demetris; Michael Nalesnik; Yan P Yu; Sarangarajan Ranganathan; George K Michalopoulos
Journal:  Hepatology       Date:  2006-10       Impact factor: 17.425

Review 2.  Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and china.

Authors:  Peipei Song; Jianjun Gao; Yoshinori Inagaki; Norihiro Kokudo; Kiyoshi Hasegawa; Yasuhiko Sugawara; Wei Tang
Journal:  Liver Cancer       Date:  2013-01       Impact factor: 11.740

3.  Multi-omics in prognosis of hepatocellular carcinoma.

Authors:  Anna Lena Ress; Rishi Wagle; Martin Pichler
Journal:  Ann Transl Med       Date:  2015-01

4.  Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis.

Authors:  Amit G Singal; Hari S Conjeevaram; Michael L Volk; Sherry Fu; Robert J Fontana; Fred Askari; Grace L Su; Anna S Lok; Jorge A Marrero
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-02-28       Impact factor: 4.254

Review 5.  Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma.

Authors:  Pei-Pei Song; Ju-Feng Xia; Yoshinori Inagaki; Kiyoshi Hasegawa; Yoshihiro Sakamoto; Norihiro Kokudo; Wei Tang
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

6.  DKK1 as a serum biomarker for hepatocellular carcinoma.

Authors:  Peter A Prieto; Charles H Cha
Journal:  Hepatobiliary Surg Nutr       Date:  2013-06       Impact factor: 7.293

7.  Screening process failures for hepatocellular carcinoma.

Authors:  Amit G Singal; Jorge A Marrero; Adam Yopp
Journal:  J Natl Compr Canc Netw       Date:  2014-03-01       Impact factor: 11.908

8.  Early Detection of Cancer: Immunoassays for Plasma Tumor Markers.

Authors:  Danni L Meany; Lori J Sokoll; Daniel W Chan
Journal:  Expert Opin Med Diagn       Date:  2009-11-01

9.  Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail?

Authors:  Amit G Singal; Mahendra Nehra; Beverley Adams-Huet; Adam C Yopp; Jasmin A Tiro; Jorge A Marrero; Anna S Lok; William M Lee
Journal:  Am J Gastroenterol       Date:  2013-01-22       Impact factor: 10.864

10.  Survival of hepatocellular carcinoma in Puerto Rico.

Authors:  Carlos Romero Marrero; Ana P Ortiz; Cynthia M Pérez; Javier Pérez; Esther A Torres
Journal:  P R Health Sci J       Date:  2009-06       Impact factor: 0.705

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.